Saturday 17 October 2026
Export HRMY’s income statement to Excel — free account
Harmony Biosciences Holdings, Inc.
HRMY Healthcare Biotechnology
Harmony Biosciences Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $868.5 million, up 21.5% from fiscal 2024. In the quarter to June 2026, revenue grew 30.3%, EPS grew 88.4%, free cash flow grew 16.5% and total debt fell 10.5%, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for five.
38.20
0.07
−0.18%
Follow HRMY
| Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
— | — | — | — | 7 | 5 | 4 | 7 | 5 |
P/E ratio |
— | — | 0.00 | 0.00 | 71.07 | 17.31 | 14.25 | 13.44 | 13.61 |
Altman Z-Score |
— | — | — | 0.96 | 6.51 | 8.46 | 5.02 | 5.29 | 5.23 |
P/S ratio |
— | — | 0.00 | 5.83 | 8.03 | 7.16 | 3.15 | 2.74 | 2.48 |
P/FCF ratio |
— | — | 0.00 | 0.00 | 0.00 | 30.05 | 10.23 | 10.96 | 6.99 |
Altman Z″-Score (non-manufacturers) |
— | — | (21.50) | (1.18) | 2.23 | 4.57 | 4.76 | 5.98 | 7.17 |
Beneish M-Score |
— | — | — | 19.29 | (2.43) | (1.55) | (2.64) | (2.64) | (2.99) |
P/Operating CF |
— | — | 59.79 | 92.73 | 65.36 | 117.47 | 23.88 | 25.91 | 17.05 |
P/B ratio |
— | — | 0.00 | 9.59 | 13.15 | 7.78 | 3.92 | 2.97 | 2.47 |
Price to Tangible BV |
— | — | 0.00 | 0.00 | 57.60 | 12.96 | 5.55 | 3.59 | 2.76 |
EV/Sales |
— | — | 0.00 | 5.62 | 7.89 | 6.86 | 2.87 | 2.34 | 1.77 |
EV/EBITDA |
— | — | 0.00 | 30.28 | 22.20 | 20.73 | 7.74 | 7.82 | 6.61 |
EV/Operating CF |
— | — | (8.62) | (300.60) | 24.46 | 20.78 | 7.62 | 7.59 | 4.42 |
EV/FCF |
— | — | (8.62) | (296.82) | (1,384.74) | 28.79 | 9.33 | 9.34 | 5.00 |
Quick Ratio |
— | 11.55 | 1.44 | 1.86 | 5.01 | 4.79 | 2.61 | 3.14 | 3.46 |
Current Ratio |
— | 11.99 | 1.58 | 1.95 | 5.29 | 5.07 | 2.75 | 3.31 | 3.60 |
Net Debt/EBITDA |
— | (5.83) | (0.52) | (1.16) | (0.39) | (0.91) | (0.74) | (1.35) | (2.63) |
Debt/Assets |
0.00% | 363.12% | 91.79% | 45.48% | 44.29% | 28.44% | 23.85% | 17.94% | 12.87% |
Debt/Equity |
— | (1.34) | (8.45) | 2.00 | 1.03 | 0.48 | 0.41 | 0.27 | 0.19 |
Asset Turnover |
— | 0.00 | 0.06 | 0.60 | 0.71 | 0.79 | 0.78 | 0.79 | 0.76 |
Operating CF/Net income |
— | 0.55 | 0.40 | 0.05 | 2.85 | 0.80 | 1.70 | 1.51 | 2.19 |
Capex/Depreciation |
— | 0.00 | (33.44) | (0.16) | (4.76) | (1.63) | (0.01) | (0.05) | (0.01) |
Interest Coverage |
— | (53.78) | (24.02) | 0.60 | 3.62 | 6.39 | 8.08 | 10.91 | 14.23 |
| — | 21.06% | 56.26% | 39.21% | 24.39% | 61.58% | 29.63% | 25.84% | 20.75% | |
| — | (156.99%) | (191.04%) | (23.92%) | 8.04% | 32.78% | 17.35% | 16.07% | 13.98% | |
ROIC |
— | 0.00% | (147.31%) | 16.91% | 37.94% | 27.68% | 39.08% | 32.13% | 50.40% |
Return on Tangible Assets |
— | (86.49%) | (1,447.30%) | (49.38%) | 14.95% | 56.36% | 44.79% | 35.89% | 24.23% |
Average Days of Receivables |
— | — | 259.06 | 50.67 | 41.64 | 45.63 | 46.50 | 42.40 | 40.68 |
Research and Development Expense of Revenue |
— | 0.00% | 1,160.88% | 12.17% | 9.94% | 16.19% | 13.07% | 20.40% | 21.83% |
Selling, General and Administrative Expense of Revenue |
— | 0.00% | 1,346.57% | 59.83% | 43.23% | 37.30% | 33.11% | 30.96% | 31.33% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.68 | 0.38 | 0.33 | 0.24 | 0.17 | 0.11 | 0.07 |
Share Based Compensation of Revenue |
— | — | 165.29% | 2.94% | 5.13% | 5.98% | 5.45% | 5.96% | 5.17% |
Graham Net Nets |
— | — | 0.34 | (0.07) | 0.02 | 0.04 | 0.06 | 0.12 | 0.24 |
Graham Number |
— | — | 0.00 | 0.00 | 6.62 | 21.65 | 19.54 | 25.83 | 30.60 |
Earnings Yield |
— | — | (25.70%) | (14.11%) | 1.41% | 5.78% | 7.02% | 7.44% | 7.35% |
Free Cash Flow Yield |
— | — | (33.68%) | (0.32%) | (0.07%) | 3.33% | 9.78% | 9.13% | 14.31% |
Revenue per Share |
— | 0.00 | 0.77 | 6.20 | 5.31 | 7.40 | 9.79 | 12.56 | 15.11 |
Operating CF per Share |
— | (0.61) | (9.70) | (0.12) | 1.71 | 2.44 | 3.69 | 3.86 | 6.06 |
Capex per Share |
— | 0.00 | (16.35) | (0.08) | (1.74) | (0.68) | (0.01) | (0.02) | (0.01) |
Free Cash Flow per Share |
— | (0.61) | (26.05) | (0.19) | (0.03) | 1.76 | 3.68 | 3.84 | 6.05 |
Cash per Share |
— | 1.31 | 3.14 | 8.87 | 4.07 | 5.46 | 5.94 | 8.21 | 13.49 |
Shareholders Equity per Share |
— | (3.81) | (1.49) | 3.77 | 3.24 | 6.81 | 7.85 | 11.59 | 15.14 |
Interest Debt per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
— | (3.81) | (1.49) | 3.77 | 3.24 | 6.81 | 7.85 | 11.59 | 15.14 |
Free Cash Flow |
— | (38.80) | (202.58) | (4.99) | (1.74) | 104.29 | 219.08 | 218.67 | 347.89 |
Working Capital |
— | 79.45 | 11.61 | 128.35 | 230.66 | 321.40 | 287.29 | 404.17 | 654.88 |
Capital Expenditures |
— | (1.34) | (127.15) | (2.00) | (100.30) | (40.17) | (0.31) | (1.15) | (0.31) |
Net Current Asset Value |
— | (245.27) | (86.79) | (67.00) | 37.50 | 129.25 | 106.61 | 239.21 | 505.60 |
EV/EBIT |
— | — | 0.00 | 52.82 | 27.54 | 24.98 | 8.70 | 8.75 | 7.39 |
Capex to Sales |
— | — | 21.21 | 0.01 | 0.33 | 0.09 | 0.00 | 0.00 | 0.00 |
Price to Operating Income |
— | — | 0.00 | 54.85 | 28.03 | 26.07 | 9.54 | 10.26 | 10.32 |
| Other line items | |||||||||
Depreciation/Fixed assets |
— | 0.12 | 2.86 | 13.49 | 25.70 | 42.96 | 64.47 | 17.94 | 0.00 |
Cash ROIC |
— | (23.51%) | (182.81%) | (0.96%) | (0.28%) | 11.37% | 21.60% | 16.75% | 19.23% |
Accounts Receivable Turnover |
— | — | 0.45 | 12.09 | 10.71 | 9.78 | 9.03 | 9.09 | 9.66 |
Accounts Payable Turnover |
— | 0.05 | 0.40 | 6.22 | 31.22 | 34.88 | 11.27 | 9.96 | 12.62 |
Inventory Turnover |
— | 0.00 | 0.64 | 11.30 | 13.45 | 19.13 | 25.10 | 24.97 | 31.60 |
Average Days of Payables |
— | 2,900.16 | 1,472.04 | 33.63 | 6.58 | 16.55 | 53.38 | 31.99 | 32.56 |
Days of Inventory on Hand |
— | 0.00 | 251.82 | 50.31 | 29.14 | 18.79 | 16.15 | 16.75 | 9.86 |
Average Receivables |
— | — | 13.22 | 13.22 | 28.51 | 44.79 | 64.44 | 78.59 | 89.91 |
Average Payables |
— | 3.91 | 3.91 | 4.46 | 1.78 | 2.39 | 10.76 | 15.74 | 15.72 |
Average Inventory |
— | — | 2.46 | 2.46 | 4.13 | 4.36 | 4.83 | 6.28 | 6.28 |
Average Assets |
— | 44.64 | 97.99 | 266.89 | 430.26 | 553.66 | 742.66 | 905.32 | 1,135.42 |
Average Common Equity |
— | (332.77) | (332.77) | (162.84) | 141.84 | 294.67 | 434.92 | 563.07 | 764.69 |
Columns are period end dates